NOTIFICATION BY PRIMARY INSIDERS/RELATED PARTIES TO ONCOINVENT ASA

Details of the Primary Insider/Related Party		
Name	Charles Gillies O'Bryan-Tear	
Reason for the notificat	ion	
Position/status	Primary insider and chairperson of the bo	ard of directors
Initial notification/	Initial notification	
Details of the company		
Name	Oncoinvent ASA	
LEI	213800TYYFXKYF3V2A23	
Details of the transaction	on(s): section to be repeated for (i) ea	ch type of instrument;
(ii) each type of transac conducted	tion; (iii) each date; and (iv) each place where transactions have been	
Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.	
Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
Price(s) and volume(s)	Price(s)	Volume(s)
	NOK 0	420,938
Aggregated information — Aggregated volume — Price	Allocation of a total of 420,938 consideration shares for a total amount of NOK 0.	
Date of the transaction	2025-11-03	
Place of transaction	Outside a trading venue	
	Reason for the notificate Position/status Initial notification/ Amendment Details of the company Name LEI Details of the transaction (ii) each type of transaction Description of the financial instrument, type of instrument Nature of the transaction Price(s) and volume(s) Aggregated information — Aggregated volume — Price Date of the transaction	Reason for the notification Position/status Primary insider and chairperson of the bound initial notification/ Amendment Details of the company Name Oncoinvent ASA LEI 213800TYYFXKYF3V2A23 Details of the transaction(s): section to be repeated for (i) each type of transaction; (iii) each date; and (iv) each place conducted Description of the financial instrument, type of instrument Nature of the transaction Allocation of consideration shares in mergen 935 506 220) and the former Oncoinvent ASA Price(s) and volume(s) Price(s) NOK 0 Aggregated information Aggregated volume Price Date of the transaction 2025-11-03

1	Details of the Primary Insider/Related Party		
a)	Name	Gro Elisabeth Hjellum	
2	Reason for the notificati	on	
a)	Position/status	Primary insider and Chief Operating Office	er
b)	Initial notification/ Amendment	Initial notification	
3	Details of the company		
a)	Name	Oncoinvent ASA	
b)	LEI	213800TYYFXKYF3V2A23	
4	Details of the transactio	n(s): section to be repeated for (i) ea	ch type of instrument;
	(ii) each type of transact conducted	ion; (iii) each date; and (iv) each place where transactions have been	
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.	
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	48,107
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 48,107 consideration shares for a total amount of NOK 0.	
e)	Date of the transaction	2025-11-03	
f)	Place of transaction	Outside a trading venue	

1	Details of the Primary Insider/Related Party			
a)	Name	Kristine Lofthus		
2	Reason for the notificat	ion		
a)	Position/status	Primary insider and Chief Production Office	cer	
b)	Initial notification/ Amendment	Initial notification		
3	Details of the company	1		
a)	Name	Oncoinvent ASA		
b)	LEI	213800TYYFXKYF3V2A23		
4	Details of the transaction	on(s): section to be repeated for (i) ea	ch type of instrument;	
	(ii) each type of transact	ion; (iii) each date; and (iv) each place where transactions have been		
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.		
b)	Nature of the transaction	935 506 220) and the former Oncoinvent	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		NOK 0	8,017	
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 8,017 consideration shares for a total amount of NOK 0.		
e)	Date of the transaction	2025-11-03	2025-11-03	
f)	Place of transaction	Outside a trading venue		

1	Details of the Primary Insider/Related Party		
a)	Name Stian Brekke		
2	Reason for the notificati	ion	
a)	Position/status	Primary insider and Head of Regulatory Af	ffairs
b)	Initial notification/ Amendment	Initial notification	
3	Details of the company		
a)	Name	Oncoinvent ASA	
b)	LEI	213800TYYFXKYF3V2A23	
4	Details of the transaction	on(s): section to be repeated for (i) ea	ch type of instrument;
	(ii) each type of transact conducted	ion; (iii) each date; and (iv) each place where transactions have been	
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.	
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	45,100
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 45,100 consideration shares for a total amount of NOK 0.	
e)	Date of the transaction	2025-11-03	
f)	Place of transaction	Outside a trading venue	

1	Details of the Primary Insider/Related Party		
a)	Name	Anne Cecilie Alvik	
2	Reason for the notificati	ion	
a)	Position/status	Primary insider and Head of Quality Assur	rance
b)	Initial notification/ Amendment	Initial notification	
3	Details of the company		
a)	Name	Oncoinvent ASA	
b)	LEI	213800TYYFXKYF3V2A23	
4	Details of the transaction	on(s): section to be repeated for (i) ea	ch type of instrument;
	(ii) each type of transact conducted	ion; (iii) each date; and (iv) each place where transactions have been	
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.	
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	15,875
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 15,875 consideration shares for a total amount of NOK 0.	
e)	Date of the transaction	2025-11-03	
f)	Place of transaction	Outside a trading venue	

1	Details of the Primary Insider/Related Party			
a)	Name	Abakus Invest AS		
2	Reason for the notificat	ion		
a)	Position/status	Close associate to primary insider and Ch	ief Executive Officer, Øystein Soug.	
b)	Initial notification/ Amendment	Initial notification		
3	Details of the company	1		
a)	Name	Oncoinvent ASA		
b)	LEI	213800TYYFXKYF3V2A23		
4	Details of the transaction	on(s): section to be repeated for (i) ea	nch type of instrument;	
	(ii) each type of transact	ion; (iii) each date; and (iv) each place where transactions have been		
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.		
b)	Nature of the transaction	935 506 220) and the former Oncoinvent	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		NOK 0	180,402	
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 180,402 consideration shares for a total amount of NOK 0.		
e)	Date of the transaction	2025-11-03		
f)	Place of transaction	Outside a trading venue		

1	Details of the Primary Insider/Related Party		
a)	Name Hadean Capital I AS		
2	Reason for the notificat	ion	
a)	Position/status	Close associate to primary insider and boa Ingrid Teigland Akay.	ard member of the board of directors,
b)	Initial notification/ Amendment	Initial notification	
3	Details of the company		
a)	Name	Oncoinvent ASA	
b)	LEI	213800TYYFXKYF3V2A23	
4	Details of the transaction	on(s): section to be repeated for (i) ea	ch type of instrument;
	(ii) each type of transact conducted	cion; (iii) each date; and (iv) each place where transactions have been	
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.	
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	10,621,231
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 10,621,231 consideration shares for a total amount of NOK 0.	
e)	Date of the transaction	2025-11-03	
f)	Place of transaction	Outside a trading venue	

1	Details of the Primary Insider/Related Party		
a)	Name	ne HVentures Capital I AB	
2	Reason for the notificati	on	
a)	Position/status	Close associate to primary insider and boa Ingrid Teigland Akay.	ard member of the board of directors,
b)	Initial notification/ Amendment	Initial notification	
3	Details of the company		
a)	Name	Oncoinvent ASA	
b)	LEI	213800TYYFXKYF3V2A23	
4	Details of the transactio	n(s): section to be repeated for (i) ea	ch type of instrument;
	(ii) each type of transact conducted	ion; (iii) each date; and (iv) each place where transactions have been	
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.	
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	4,817,485
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 4,817,485 consideration shares for a total amount of NOK 0.	
e)	Date of the transaction	2025-11-03	
f)	Place of transaction	Outside a trading venue	

1	Details of the Primary Insider/Related Party			
a)	Name	Teakay Invest AS		
2	Reason for the notificati	on		
a)	Position/status	Close associate to primary insider and boa Ingrid Teigland Akay.	Close associate to primary insider and board member of the board of directors,	
b)	Initial notification/ Amendment	Initial notification		
3	Details of the company			
a)	Name	Oncoinvent ASA		
b)	LEI	213800TYYFXKYF3V2A23		
4	Details of the transactio	n(s): section to be repeated for (i) ea	ch type of instrument;	
	(ii) each type of transact conducted	ion; (iii) each date; and (iv) each place where transactions have been		
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.		
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		NOK 0	297,187	
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 297,187 consideration shares for a total amount of NOK 0.		
e)	Date of the transaction	2025-11-03		
f)	Place of transaction	Outside a trading venue		

1	Details of the Primary Insider/Related Party		
a)	Name	Itza AS	
2	Reason for the notificati	on	
a)	Position/status	Close associate to primary insider and Chi	ef Financial Officer, Tore Kvam.
b)	Initial notification/ Amendment	Initial notification	
3	Details of the company		
a)	Name	Oncoinvent ASA	
b)	LEI	213800TYYFXKYF3V2A23	
4	Details of the transactio	n(s): section to be repeated for (i) ea	ch type of instrument;
	(ii) each type of transact conducted	ion; (iii) each date; and (iv) each place where transactions have been	
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.	
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		NOK 0	72,160
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 72,160 consideration shares for a total amount of NOK 0.	
e)	Date of the transaction	2025-11-03	
f)	Place of transaction	Outside a trading venue	

1	Details of the Primary Insider/Related Party			
a)	Name K OG K AS			
2	Reason for the notificati	on		
a)	Position/status	Close associate to primary insider and boa	Close associate to primary insider and board member of the board of directors, Kari Grønås	
b)	Initial notification/ Amendment	Initial notification		
3	Details of the company			
a)	Name	Oncoinvent ASA		
b)	LEI	213800TYYFXKYF3V2A23		
4	Details of the transactio	n(s): section to be repeated for (i) ea	ch type of instrument;	
	(ii) each type of transact conducted	ion; (iii) each date; and (iv) each place where transactions have been		
a)	Description of the financial instrument, type of instrument	Shares in Oncoinvent ASA with ISIN NO0013251173.		
b)	Nature of the transaction	Allocation of consideration shares in merger between BerGenBio Norge AS (reg. no. 935 506 220) and the former Oncoinvent ASA (reg. no. 995 764 458), with issuance of consideration shares in Oncoinvent ASA (reg. no. 992 219 688).		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		NOK 0	90,201	
d)	Aggregated information — Aggregated volume — Price	Allocation of a total of 90,201 consideration shares for a total amount of NOK 0.		
e)	Date of the transaction	2025-11-03		
f)	Place of transaction	Outside a trading venue		